UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C.  20549
                                 ____________

                                  FORM 10-Q

              QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                     THE SECURITIES EXCHANGE ACT OF 1934
               For the Quarterly Period Ended September 30, 2004
                        Commission File Number 0-7491
                                 ____________

                              MOLEX INCORPORATED
            (Exact name of registrant as specified in its charter)

                    Delaware                      36-2369491
         (State or other jurisdiction of       (I.R.S.  Employer
         incorporation or organization)       Identification No.)

               2222 Wellington Court, Lisle, Illinois  60532
                  (Address of principal executive offices)
    Registrant's telephone number, including area code:  (630) 969-4550
                                 ____________

             Indicate by check mark whether the registrant  (1)  has
        filed  all reports required to be filed by Section 13 or  15
        (d)  of  the  Securities Exchange Act  of  1934  during  the
        preceding  12  months (or for such shorter period  that  the
        registrant was required to file such reports), and  (2)  has
        been  subject to such filing requirements for  the  past  90
        days.     Yes x      No

             Indicate  by  check mark whether the registrant  is  an
        accelerated filer (as defined in Rule 12b-2 of the  Exchange
        Act).   Yes x      No

             On  September 30, 2004, the following numbers of shares
        of the Company's common stock were outstanding:

                    Common Stock             100,553,124
                    Class A Common Stock      87,769,304
                    Class B Common Stock          94,255



             The financial statements included in this Quarterly Report
        on Form 10-Q have not been reviewed by an independent public
        accountant as required by Rule 10-01(d) of Regulation S-X. See
        "Statement Regarding Review of Financial Statements" in Item 1
        of Part I of this Report.




                              Molex Incorporated

                                     INDEX



     PART I - FINANCIAL INFORMATION

      Item 1. Financial Statements                                      Page

              Statement Regarding Review of Financial Statements          3

              Condensed Consolidated Balance Sheets
              September 30, 2004 and June 30, 2004                        4

              Condensed Consolidated Statements of Income
              Three Months Ended September 30, 2004 and 2003              5

              Condensed Consolidated Statements of Cash Flows
              Three Months Ended September 30, 2004 and 2003              6

              Notes to Condensed Consolidated Financial Statements        7

      Item 2. Management's Discussion and Analysis of Results
              of Operations and Financial Condition                      11

      Item 3. Quantitative and Qualitative Disclosure About Market Risk  14

      Item 4. Controls and Procedures                                    15


     PART II - OTHER INFORMATION

      Item 2. Unregistered Sales of Equity Securities
              and Use of Proceeds                                        15

      Item 4. Submission of Matters to a Vote of Security Holders        15

      Item 5. Other Information                                          16

      Item 6. Exhibits                                                   17


     SIGNATURES                                                          19


                                       2






                                PART I

Item 1.  Financial Statements


        Statement Regarding Review of Financial Statements

     This Quarterly Report on Form 10-Q contains financial
statements for the fiscal quarter ended September 30, 2004, which
have not been reviewed by an independent public accountant as
required by Rule 10-01(d) of Regulation S-X because Deloitte &
Touche LLP, Molex's previous independent public accounting firm,
resigned on November 13, 2004.  For additional information
regarding this matter, please refer to Item 5 of Part II below and
our Current Report on Form 8-K being filed on the date hereof.

     Molex expects to engage a new independent registered public
accounting firm shortly and that the review of its financial
statements for the fiscal quarter ended September 30, 2004 will be
completed as soon as practicable following Molex's engagement of a
new accounting firm.  Upon the completion of such review, Molex
intends to file an amendment to this Quarterly Report on Form 10-Q.
Molex believes that the following unaudited financial
statements and notes thereto include all adjustments necessary for
a fair presentation of the consolidated financial position and
results from operations for the periods presented.





                                       3






                              Molex Incorporated
                    Condensed Consolidated Balance Sheets
                    (In thousands, except per share data)


                                                    Sept. 30,     June 30,
                                                      2004          2004
                                                   -----------   -----------
ASSETS                                             (Unaudited)
Current assets:
Cash and cash equivalents                          $   238,292   $   234,431
Marketable securities                                   93,153       104,223
Accounts receivable, net                               544,736       529,630
Inventories                                            283,417       265,344
Other current assets                                    40,027        35,016
                                                   -----------   -----------
 Total current assets                                1,199,625     1,168,644
Property, plant and equipment, net                   1,009,163     1,022,378
Goodwill                                               164,969       164,915
Other assets                                           194,930       216,409
                                                   -----------   -----------
 Total assets                                      $ 2,568,687   $ 2,572,346
                                                   -----------   -----------

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable                                   $   225,731   $   234,823
Accrued expenses                                       132,625       143,160
Other current liabilities                               47,508        50,481
                                                   -----------   -----------
 Total current liabilities                             405,864       428,464
Other non-current liabilities                            9,361        10,487
Accrued pension and postretirement benefits             51,435        52,151
Long-term debt                                          10,075        10,243
Obligations under capital leases                         3,143         3,796
Minority interest in subsidiaries                        3,383         1,211
Shareholders' equity:
Common Stock                                            10,747        10,734
Paid-in capital                                        376,518       369,660
Retained earnings                                    2,209,211     2,160,368
Treasury stock                                        (532,216)     (509,161)
Deferred unearned compensation                         (32,722)      (32,180)
Accumulated other comprehensive income                  53,888        66,573
                                                   -----------   -----------
Total shareholders' equity                           2,085,426     2,065,994
                                                   -----------   -----------
 Total liabilities and shareholders' equity        $ 2,568,687   $ 2,572,346
                                                   -----------   -----------


The accompanying notes are an integral part of these condensed
consolidated financial statements.

                                       4



                              Molex Incorporated
                  Condensed Consolidated Statements of Income
               (Unaudited - in thousands, except per share data)


                                                       Three Months Ended
                                                          September 30,
                                                   -------------------------
                                                      2004           2003
                                                   -----------   -----------
Net revenue                                        $   640,230   $   496,763
Cost of sales                                          411,558       328,739
                                                   -----------   -----------
 GROSS PROFIT                                          228,672       168,024
                                                   -----------   -----------
Selling, general and administrative expenses:
 Selling                                                54,020        44,416
 General and administrative                            102,192        83,048
                                                   -----------   -----------
 Total selling, general and
  administrative expenses                              156,212       127,464
                                                   -----------   -----------
INCOME FROM OPERATIONS                                  72,460        40,560

Other (income) expense:
 Equity income                                          (2,029)       (2,183)
 (Gain)/loss on investments                             (1,152)            -
 Interest, net                                            (925)       (1,235)
                                                   -----------   -----------
 Total other (income) expense                           (4,106)       (3,418)

INCOME BEFORE INCOME TAXES
  AND MINORITY INTEREST                                 76,566        43,978

 Income taxes and minority interest                     20,924        11,916
                                                   -----------   -----------
NET INCOME                                         $    55,642   $    32,062
                                                   -----------   -----------
EARNINGS PER SHARE:
 Basic                                             $      0.29   $      0.17
 Diluted                                           $      0.29   $      0.17

DIVIDENDS PER SHARE                                $    0.0375   $    0.0250

AVERAGE COMMON SHARES OUTSTANDING:
 Basic                                                 188,763       190,679
 Diluted                                               190,617       192,372






The accompanying notes are an integral part of these condensed
consolidated financial statements.

                                       5





                              Molex Incorporated
               Condensed Consolidated Statements of Cash Flows
                          (Unaudited - In thousands)

                                                       Three Months Ended
                                                          September 30,
                                                   ------------------------
                                                       2004          2003
                                                   -----------   -----------
                                                              Restated (Note 2)

Cash and cash equivalents, beginning of period     $   234,431   $   178,976

OPERATING ACTIVITIES
Net income                                              55,642        32,062
Add (deduct) non-cash items included in net income:
 Depreciation and amortization                          57,193        55,475
 Amortization of deferred unearned compensation          3,787         3,007
Changes in assets and liabilities, excluding effects of
foreign currency adjustments:
 Accounts receivable                                   (14,632)      (36,008)
 Inventories                                           (18,144)      (13,767)
 Accounts payable                                       (7,332)        7,121
 Other current assets and liabilities                  (20,328)      (10,953)
 Other assets and liabilities                           (1,770)        5,972
                                                   -----------   -----------
Cash provided from operating activities                 54,416        42,909

INVESTING ACTIVITIES
Capital expenditures                                   (48,435)      (45,324)
Sales (purchases) of marketable securities              11,036         9,387
Other investing activities                              13,275        (2,059)
                                                   -----------   -----------
Cash used for investing activities                     (24,124)      (37,996)

FINANCING ACTIVITIES
Net decrease in debt                                       (65)       (2,855)
Principal payments on capital leases                      (827)       (1,362)
Cash dividends paid                                     (4,730)       (4,773)
Purchase of treasury stock                             (21,905)      (19,985)
Reissuance of treasury stock                               213           539
Exercise of stock options                                1,360         2,177
                                                   -----------   -----------
Cash used for financing activities                     (25,954)      (26,259)

Effect of exchange rate changes on
 cash and cash equivalents                                (477)        1,164
                                                   -----------   -----------
Net increase (decrease) in cash and
 cash equivalents                                        3,861       (20,182)
                                                   -----------   -----------
Cash and cash equivalents, end of period           $   238,292   $   158,794
                                                   -----------   -----------


The accompanying notes are an integral part of these condensed
consolidated financial statements.

                                       6




                              Molex Incorporated
              Notes to Condensed Consolidated Financial Statements
                                  (Unaudited)


1.   Basis of Presentation

     Molex   Incorporated   manufactures  electronic   components,
including electrical and fiber optic interconnection products  and
systems,  switches  and integrated products in  55  plants  in  19
countries throughout the world.

     The  unaudited  financial statements have been prepared  from
the  Company's books and records and reflect all adjustments that,
in   the   opinion  of  management,  are  necessary  for  a   fair
presentation  of  information for the interim  periods  presented.
The condensed consolidated financial statements have been prepared
pursuant  to  the  rules  and regulations of  the  Securities  and
Exchange  Commission and therefore, do not include all information
and  footnote  disclosures  included in  the  annual  consolidated
financial statements.  These financial statements should  be  read
in  conjunction  with  the consolidated financial  statements  and
notes  thereto  included  in the Molex  Incorporated  2004  Annual
Report  on  Form 10-K.  The results of operations for the  interim
periods  should  not be considered indicative  of  results  to  be
expected for the full year.

     Certain reclassifications have been made to the prior  year's
financial   statements  to  conform  to  the  fiscal   year   2005
classifications.

2.  Restatement of Cash Flow Activities

     During  the  fourth  quarter  of  fiscal  2004,  the  Company
implemented  a  new  process to capture and  analyze  the  various
financial  data  used  in  the  preparation  of  the  consolidated
statement  of cash flows. The new financial reporting process  was
designed to improve management's ability to analyze and review all
significant  cash  flow activity. During the testing  of  the  new
process,  the  Company determined that certain  changes  in  other
assets  and  liabilities that historically had  been  reported  as
investing  activities  should  have  been  reported  as  operating
activities.

     As reported in the Molex Incorporated 2004 Annual Report on
Form 10-K, cash provided from operating activities and cash used for
investing activities was restated in the consolidated statement of
cash  flows  for  the  year ended June 30,  2003  as  follows  (in
thousands):

                                                      Previously
                                           Restated    Reported
                                          ---------   ----------

Cash provided from operating activities   $ 304,872   $ 349,473
                                          ---------   ----------

Cash used for investing activities        $(249,225)  $(293,826)
                                          ---------   ----------

     The  impact  on reported cash flow activity related  to  this
issue  was  not  material for the Company's fiscal  2004  quarters
ended  March  31, December 31 and September 30.

     During   the  first  quarter  of  fiscal  2005,  the  Company
determined  that  it had made a clerical error, unrelated  to  the
issue discussed above, in the condensed consolidated statement  of
cash flows for the three months ended September 30, 2003.

                                       7

     Cash  provided  from operating activities and the  effect  of
exchange  rate  changes  on  cash and cash  equivalents  has  been
restated in the condensed consolidated statement of cash flows for
the   three  months  ended  September  30,  2003  as  follows  (in
thousands):

                                                      Previously
                                           Restated    Reported
                                          ---------   ----------

Cash provided from operating activities    $ 42,909   $  31,909
                                          ---------   ----------
Effect of exchange rate changes on
 cash and cash equivalents                 $  1,164   $  12,164
                                          ---------   ----------

3.   Prior Year Adjustment

     Included in the results for the three months ended September
30, 2004 is a charge of $8.0 million ($5.8 million after-tax, or
$0.03 per share), of which $3.0 million ($2.2 million after-tax)
related to fiscal 2004. This adjustment related to the omission of
certain intercompany inventory in the Company's calculation  of
profit-in-inventory elimination. The  Company  has concluded that
the amounts related to fiscal 2004 and prior years are not material,
both individually and in the aggregate, to the trends of the financial
statements for those periods affected, and to a fair presentation
of the Company's results of operations and financial statements.
Accordingly, results for fiscal 2004 and prior years have not been
restated.

     Also included in the results for the three months ended
September 30, 2004 is a reversal of a prior year insurance accrual
of $2.7 million ($2.0 million after-tax), which was no longer required
and a reduction in inventory allowance of $1.5 million ($1.1 million
after-tax).

4.   Earnings Per Share

     A reconciliation of the basic average common shares
outstanding to dilutive average common shares outstanding is as
follows (in thousands):

                                                       Three Months Ended
                                                          September 30,
                                                       ------------------
                                                         2004      2003
                                                       --------  --------

Basic average common shares outstanding                 188,763   190,679
Effect of dilutive stock options                          1,854     1,693
                                                       --------  --------
Diluted average common shares outstanding               190,617   192,372
                                                       --------  --------
5.    Comprehensive Income

     Total comprehensive income is summarized as
follows (in thousands):

                                                       Three Months Ended
                                                          September 30,
                                                       ------------------
                                                         2004      2003
                                                       --------  --------

Net income                                             $ 55,642  $ 32,062
Translation adjustments                                 (12,672)   21,698
Unrealized investment gain (loss)                           (13)      242
                                                       --------  --------
Total comprehensive income                             $ 42,957  $ 54,002
                                                       --------  --------
                                       8


6.   Inventories

     Inventories  are  valued at the lower of first-in,  first-out
cost  or market.  Inventories, net of allowances, consist  of  the
following (in thousands):

                                                      Sept. 30,   June 30,
                                                        2004        2004
                                                      ---------   ---------
Raw materials                                         $  39,762   $  39,743
Work in process                                          95,029      91,168
Finished goods                                          148,626     134,433
                                                      ---------   ---------
Total inventories                                     $ 283,417   $ 265,344
                                                      ---------   ---------

7.   Pensions and Other Postretirement Benefits

     The components of pension and retiree health care benefit
cost are as follows for the three months ended September 30, 2004
and 2003 (in thousands).

                                           Pension        Retiree Health Care
                                       ----------------   -------------------
                                         2004    2003       2004       2003
                                       -------  -------   --------   --------

Service cost                           $ 1,997  $ 1,754   $   470    $   485
Interest cost                              952    1,225       471        499
Expected return on plan assets          (1,047)  (1,221)        -          -
Amortization of prior service cost          51       60       (66)       (68)
Recognized actuarial losses                349      172       159        189
Amortization of transition obligation       15       17         -          -
                                       -------  -------   -------    -------
Benefit cost                           $ 2,317  $ 2,007   $ 1,034    $ 1,105
                                       -------  -------   -------    -------

8.   Stock Option Plans

     As  permitted by Statement of Financial Accounting  Standards
(SFAS)  No.  123,  "Accounting for Stock-Based Compensation",  the
Company  has  elected to account for its stock-based  compensation
programs  according  to  the provisions of  Accounting  Principles
Board  Opinion No. 25, "Accounting for Stock Issued to Employees."
Had  the  Company elected to apply the provisions of SFAS No.  123
regarding recognition of compensation expense to the extent of the
calculated  fair value of stock options granted,  the  effects  on
reported  net  income and earnings per share for the three  months
ended  September  30  would have been as  follows  (in  thousands,
except per share data):

                                                       Three Months Ended
                                                          September 30,
                                                       ------------------
                                                         2004      2003
                                                       --------  --------
Net income as reported                                 $ 55,642  $ 32,062
Add: Stock-based compensation included in reported
 net income, net of related tax effects                   2,765     2,196
Deduct: Stock-based compensation determined under
 fair value method, net of related tax effects           (5,881)   (3,814)
                                                       --------  --------
Pro forma net income                                   $ 52,526  $ 30,444
                                                       --------  --------
Earnings per share:
  Basic                                                $   0.29  $   0.17
  Diluted                                              $   0.29  $   0.17
Pro forma earnings per share:
  Basic                                                $   0.28  $   0.16
  Diluted                                              $   0.28  $   0.16


                                       9

     For  purposes of computing pro forma net income and  earnings
per share, the fair value of each option grant is estimated as  of
the date of grant using the Black-Scholes option pricing model.

9. Segments and Related Information

     The Company operates in one product segment:  the manufacture
and  sale  of  electronic  components.   Management  operates  the
business   through  four  regions.   Information  by   region   is
summarized as follows (in thousands):

                                      Inter-
                         Customer    Company      Total        Net
Three months ended:      Revenue     Revenue     Revenue      Income
September 30, 2004       --------    --------    --------    --------
Americas                 $176,623    $ 55,286    $231,909    $ 16,027
Far East South            190,339      36,344     226,683      25,108
Far East North            131,639      76,902     208,541      25,137
Europe                    128,414      10,589     139,003       2,625
Corporate and other        13,215      27,199      40,414     (13,255)
Eliminations                    -    (206,320)   (206,320)          -
                         --------    --------    --------    --------
Total                    $640,230    $      -    $640,230    $ 55,642
                         --------    --------    --------    --------
September 30, 2003
Americas                 $151,491    $ 38,869    $190,360    $ 10,583
Far East South            142,872      17,528     160,400      17,482
Far East North            116,313      48,693     165,006      13,653
Europe                     74,407       8,365      82,772      (1,603)
Corporate and other        11,680      26,933      38,613      (8,053)
Eliminations                    -    (140,388)   (140,388)          -
                         --------    --------    --------    --------
Total                    $496,763    $      -    $496,763    $ 32,062
                         --------    --------    --------    --------

     Revenue is recognized based on the location of the selling
entity.



10.  Subsequent Event

      On November 13, 2004, the Company was notified that its
independent auditor, Deloitte & Touche LLP, was resigning as the
Company's independent public accountant.  The Company has not yet
retained a new independent public accountant. Consequently, the
unaudited financial statements included in this Form 10-Q have not
been reviewed by an independent public accountant as required by
Rule 10-01(d) of Regulation S-X.



                                       10





                              Molex Incorporated



Item  2.   Management's Discussion and Analysis of Results of
Operations and Financial Condition

Results of Operations

First Quarter Results

     Revenue  was  $640.2  million  for  the  three  months  ended
September  30,  2004, an increase of 29 percent over  last  year's
first  quarter  of $496.8 million. Revenue for the  first  quarter
included  $18  million from the automotive acquisition  in  Europe
that  was completed on April 2, 2004. The strengthening of certain
foreign  currencies, principally the euro and  the  yen,  compared
with  the  U.S.  dollar  increased revenue  by  approximately  $19
million over the prior year quarter.

     Customer  revenue in the Americas region was $176.6  million,
up  17  percent from last year's first quarter revenue  of  $151.5
million,  due  to stronger demand for high-speed,  industrial  and
medical electronics products, which more than offset lower  demand
in  automotive. In the Far East South region, customer revenue was
$190.3  million,  an  increase of $47.5 million,  or  33  percent,
compared with the prior year first quarter. The revenue growth  in
this  region  was  primarily driven by  demand  from  the  digital
consumer, personal computer and mobile phone markets, serving both
local  and  multinational customers. Customer revenue in  the  Far
East  North region, increased 13 percent to $131.6 million in  the
first quarter of fiscal 2005, compared with $116.3 million in  the
prior year quarter.  Foreign currency translation contributed $8.8
million  to the revenue increase. Demand for new products  in  the
digital  consumer and communication markets was also  strong.   In
Europe,  customer revenue was $128.4 million, up 73  percent  from
last  year's  first  quarter revenue of $74.4  million.  As  noted
above,  the  Company's automotive acquisition  during  the  fourth
quarter  of  fiscal 2004, added revenue of $18  million.   Foreign
currency  translation,  led  by the strong  euro,  also  favorably
impacted customer revenue by approximately $8 million.

     Gross  profit  was $228.7 million for the three months  ended
September  30,  2004, up $60.7 million, or 36  percent over the
prior  year quarter. Gross profit margin was 35.7 percent  of  net
revenue,  up  from 33.8 percent in last year's first quarter.  The
improvement  in gross profit margin was primarily due to  leverage
from  the  higher sales volumes. Included in the results  for  the
three  months ended September 30, 2004 is a charge of $8.0 million
($5.8 million after-tax, or $0.03 per share) related to prior years.
This adjustment related to the omission of certain intercompany
inventory in the Company's calculation of profit-in-inventory
elimination.  See Note 3 to the Notes to Condensed Consolidated
Financial Statements for further discussion. Also included in the
results for the three months ended September 30, 2004 is a reversal
of a prior year insurance accrual  of  $2.7 million ($2.0 million
after-tax), which was no longer required, and a reduction in
inventory allowance of $1.5 million ($1.1 million after-tax).

     Selling,  general  and  administrative expenses  were  $156.2
million  for  the first three months of fiscal 2005,  as  compared
with $127.5 million in the prior year quarter. As a percent of net
revenue,  selling,  general and administrative expenses  decreased
from  25.7  percent in the prior year quarter to 24.4  percent  in
this year's first quarter.

     Total other income was $4.1 million in the first quarter
ended  September 30, 2004, compared with $3.4 million in the prior
year  quarter.  The effective tax rate was 27.0  percent  for  the
first  quarter of fiscal 2005, the same rate as last year's  first
quarter.

     Net  income for the three months ended September 30, 2004 was
$55.6  million,  up 74 percent from $32.1 million in  last  year's
first  quarter. Foreign currency translation increased net  income
by $2.0 million. Earnings per share was $0.29 in the first quarter
of fiscal 2005 compared with $0.17 in the prior year quarter.

                                       11


Financial Condition and Liquidity

     The  Company's  long-term financing strategy is  to  rely  on
internal  sources of funds for investing in plant,  equipment  and
acquisitions.   Management remains confident  that  the  Company's
liquidity  and financial flexibility are adequate to support  both
current,  as  well as future growth.  Molex has historically  used
external borrowings only when a clear financial advantage  exists.
Long-term debt at September 30, 2004 totaled $10.1 million.

     Cash provided from operating activities and the effect of
exchange rate changes on cash and cash equivalents has been restated
in the Condensed Consolidated Statement of Cash Flows for the three
months ended September 30, 2003.  See Note 2 to the Notes to
Condensed Consolidated Financial Statements for further discussion.

     Cash  provided from operating activities for the three months
ended  September 30, 2004 was $54.4 million, up from $42.9 million
in  the  prior  year period.  The increase in cash  provided  from
operations was driven by higher net income in the current  period.
For  the  three months ended September 30, 2004, cash was used  to
support  higher  working  capital  levels.   Working  capital   at
September 30, 2004 was $793.8 million compared with $740.2 million
at June 30, 2004.

     Cash  used  for  investing activities was $24.1  million  and
$38.0  million for the three months ended September 30,  2004  and
2003,  respectively.  Capital expenditures were $48.4  million  in
the  current  period, an increase of $3.1 million over  the  prior
year's  capital  spending  of $45.3  million.   During  the  first
quarter  of  fiscal 2005, the Company sold its  investment  in  an
affiliate  and  generated  cash from  this  transaction  of  $14.1
million.

     Cash  used for financing activities was $26.0 million in  the
first  quarter of fiscal 2005 compared with $26.3 million  in  the
prior  year  period.  Cash was used primarily for the purchase  of
treasury stock and the payment of dividends.  The Company's  Board
of  Directors  authorized the purchase of up to  $100  million  of
Common  Stock  and/or  Class A Common Stock  during  fiscal  2005.
During  the  three  months ended September 30, 2004,  the  Company
purchased  875,000 shares of Class A Common Stock at an  aggregate
cost of $21.9 million.

     Molex has a strong cash balance and cash flow and very little
debt.   The  Company believes at this time that share  repurchases
are  a  good investment as compared with investing cash in  short-
term money instruments or marketable securities, particularly with
the  current  low  interest rates.  The Company also  uses  shares
repurchased  to  replenish stock used for  exercises  of  employee
stock  options,  employee  stock awards  and  the  employee  stock
purchase plan.

Outlook

     Molex's  operations  in the Far East continue  to  drive  the
Company's  results.   Management expects this trend  to  continue,
based  on  the  magnitude  of  production  transferred  by  global
customers  to  the  region  and  supported  by  Molex's  technical
capabilities and long-term history of working in the region.

     In the Americas region, many customers appear to be adjusting
their  finished  goods  inventory  to  more  conservative  levels.
Management believes that the amount of actual connector  inventory
within these channels is reasonable, and therefore the outlook  in
the  majority  of  the Company's markets remains  encouraging.  In
addition,  management expects to gain market share  based  on  the
Company's  positions within key markets, such as digital consumer,
mobile communication and mobile computing, that are growing faster
than  the  overall connector market, as well as the focus  on  the
emerging medical electronics market.

     For  the  second quarter ending December 30, 2004, management
is  forecasting  revenues  in a range  of  $635  million  to  $650
million.   Based  on these revenues, the Company expects  earnings
per share in the range of $0.29 to $0.31.

                                       12


     Due  to  the  uncertainty  of the foreign  currency  exchange
markets, Molex cannot reasonably predict future trends related  to
foreign currency fluctuations.  Foreign currency fluctuations have
impacted the Company's results in the past and may impact  results
in the future.


Critical Accounting Policies

     See   the   information  concerning  the  Company's  critical
accounting  policies  included under  Management's  Discussion  of
Financial  Condition and Results of Operations  in  the  Company's
Annual  Report  on Form 10-K for the fiscal year  ended  June  30,
2004, which is incorporated in this Form 10-Q by reference.

Item  3. Quantitative and Qualitative Disclosures About Market Risk

     The Company is subject to market risk associated with changes
in  foreign  currency exchange rates, interest rates  and  certain
commodity  prices.   The Company mitigates  its  foreign  currency
exchange rate risk principally through the establishment of  local
production  facilities in the markets it serves and  invoicing  of
customers  in  the  same currency as the source of  the  products.
Molex  also monitors its foreign currency exposure in each country
and  implements  strategies to respond to  changing  economic  and
political environments.  Examples of these strategies include  the
prompt payment of intercompany balances utilizing a global netting
system,  the establishment of contra-currency accounts in  several
international  subsidiaries, development  of  natural  hedges  and
occasional  use  of  foreign  exchange  contracts  to  protect  or
preserve the value of intercompany cash flows. No material foreign
exchange contracts were in use at September 30, 2004 and 2003.

     The  Company  has  implemented  a  formalized  treasury  risk
management policy that describes the procedures and controls  over
derivative financial and commodity instruments.  Under the policy,
the  Company  does  not  use  derivative  financial  or  commodity
instruments  for  speculative  purposes,  and  the  use  of   such
instruments  is  subject  to  strict  approval  levels  by  senior
management.   Typically,  the  use of  derivative  instruments  is
limited to hedging activities related to specific foreign currency
cash flows.

     The  Company's  $93.2  million of  marketable  securities  at
September 30, 2004 are principally debt instruments that  generate
interest income for the Company on temporary excess cash balances.
These  instruments  contain  embedded  derivative  features   that
enhance the liquidity of the portfolio by enabling the Company  to
liquidate  the instrument prior to the stated maturity date.   The
Company's  exposure related to derivative instrument  transactions
is,  in  the  aggregate, not material to the  Company's  financial
position, results of operations or cash flows.

     Interest  rate  exposure is limited to marketable  securities
owned  by  the Company and long-term debt.  The Company  does  not
actively  manage the risk of interest rate fluctuations.  However,
such risk is mitigated by the relatively short-term nature of  its
investments, less than twelve months, and the fixed-rate nature of
its long-term debt.

     Molex   does  not  have  exposure  to  any  off-balance-sheet
arrangements with the exception of certain operating leases.   Due
to  the  nature  of  its  operations,  Molex  is  not  subject  to
significant concentration risks relating to customers, products or
geographic locations.

     The  Company  monitors the environmental laws and regulations
in  the countries in which it operates.  Molex has implemented  an
environmental  program  to  reduce the generation  of  potentially
hazardous materials during its manufacturing process and  believes
it continues to meet or exceed local government regulations.

Item 4.  Controls and Procedures

As  of  the  end of the period covered by this report,  Molex
conducted  an  evaluation,  under the  supervision  and  with  the
participation  of  the principal executive officer  and  principal
financial  officer, of Molex's disclosure controls and  procedures
(as  defined in Rules 13a-15(e) and 15d-15(e) under the Securities

                                       13

Exchange  Act  of  1934  (the `Exchange  Act')).   Based  on  that
evaluation,   the  principal  executive  officer   and   principal
financial officer have concluded that, except as described  below,
Molex's disclosure controls and procedures are effective to ensure
that information required to be disclosed by Molex in reports that
it files or submits under the Exchange Act is recorded, processed,
summarized  and  reported  within the time  periods  specified  in
Securities and Exchange Commission's rules and forms.

     During  the fiscal quarter ended September 30, 2004,  Molex's
management   identified  the  omission  of  certain   intercompany
inventory  in  its calculation of profit-in-inventory  elimination
for prior periods as described in Note 3 to the Notes to Condensed
Consolidated  Financial  Statements.   Molex  concluded  that  the
amounts  related to fiscal 2004 and prior years are not  material,
both  individually  and in the aggregate, to  the  trends  of  the
financial  statements for those periods affected, and  to  a  fair
presentation  of  Molex's  results  of  operations  and  financial
statements.   Molex's  Audit Committee concurs  with  management's
recommendations as to the accounting treatment for such omission.

     Molex's independent public accounting firm, Deloitte & Touche
LLP  ("Deloitte"),  expressed  to the  Audit  Committee  that  the
omission  described  above  should  have  been  disclosed  in  the
representation  letter  dated August 20,  2004  of  Molex's  Chief
Executive  Officer  and  Chief  Financial  Officer  delivered   to
Deloitte  on  September 10, 2004 in connection with the  audit  of
Molex's financial statements as of and for the year ended June 30,
2004  and  the  filing of Molex's Annual Report on  Form  10-K  on
September  10,  2004.  The signatories did not  believe  that  the
matter was required to be addressed in that letter.

     The Audit Committee, with the assistance of independent legal
and  accounting advisors, conducted an inquiry into  the  omission
and related matters.  No additional adjustments were identified as
a  result  of  this  inquiry.  The Audit Committee  presented  the
findings   of   the  inquiry  to  Deloitte.   Deloitte   requested
additional  information  relating to this  matter  and  the  Audit
Committee responded to those requests.  As disclosed in  Part  II,
Item  5  below, Deloitte ultimately advised Molex on November  13,
2004  that  Deloitte  was prepared to complete  its  review, under
Statement   of  Auditing  Standards  No.  100  "Interim  Financial
Information"  (SAS  100), of  the unaudited  financial  statements
included in this Form 10-Q in time to permit a filing of the  Form
10-Q  in substantially the form hereof by the November 15 extended
deadline  for  such  report, but only if Molex's  Chief  Executive
Officer   and   Chief  Financial  Officer  who  had   signed   the
representation  letter dated August 20, 2004 no longer  served  as
officers of Molex and certain disclosures relating to the  matters
in  question were agreed upon.   Molex's Audit Committee and Board
of  Directors each unanimously rejected this condition imposed  by
Deloitte.    Following  the  communication  of  Molex's  position,
representatives  of Deloitte advised Molex on  November  13,  2004
that  Deloitte  was  resigning  as  Molex's  independent  auditors
effective immediately.

     Molex's  management  is  not aware of any  information  which
would  result  in  any  adjustments to the  financial  information
included in this Form 10-Q.  Molex's management has established  a
remediation  plan  to correct the deficiency in internal  controls
described  above  and has discussed the plan for remediation  with
Molex's  Audit Committee.  Molex intends to continue  to  evaluate
the  effectiveness of its disclosure controls and  procedures  and
will take corrective action as appropriate.

     Except as described above, there have been no changes in  the
Company's disclosure controls and procedures in the fiscal quarter
ended  September  30, 2004 that have materially  affected  or  are
reasonably  likely  to materially affect the Company's  disclosure
controls and procedures.

                                       14




                              PART II

Item 1. Not applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     On  July  29,  2004, the Company issued options  to  purchase
88,000 shares of Class A Common Stock to employee directors of the
Company with an aggregate exercise price of $2,186,437, pursuant to
the terms of the 2000 Incentive Stock Option Plan. The issuance of
these  options  to  purchase shares of Class A  Common  Stock  was
exempt  from registration under the Securities Act of 1933,  as  a
transaction  not involving a public offering under  Section  4(2).
Per  the  terms of the plan, the option price is the  fair  market
value  of  the stock on the date of grant and the option  term  is
five years from the date of grant.

     Share  purchases of Molex Class A Common Stock  for  the
quarter ended September 30, 2004 were as follows:

                                               Total Number    Dollar Value
                                                 of Shares      of Shares
                                                Purchased as   that May Yet
                                                  Part of      Be Purchased
                    Total Number   Average       Publicly       Under the
                     of Shares     Price Paid    Announced        Plan
   Period            Purchased     Per Share       Plan
- ----------------    ------------   ----------   ------------   ------------

July 1 - July 31          -             -            -         $100,000,000

Aug. 1 - Aug. 31       635,000        $24.91       635,000      $84,179,324

Sept. 1 - Sept. 30     240,000        $25.35       240,000      $78,094,624

   Total               875,000        $25.03       875,000      $78,094,624



Item 3.  Not applicable

Item 4.  Submission of Matters to a Vote of Security Holders

     At  the  Annual Meeting of Stockholders held on  October  22,
2004,  the  following directors were elected to  hold  office  for
their  respective  terms according to their class:   Frederick  A.
Krehbiel,  76,919,923  votes  in favor  and  17,974,492  withheld;
Masahisa Naitoh, 93,471,527 votes in favor and 1,422,888 withheld;
Michael   J.  Birck,  86,868,952  votes  in  favor  and  8,025,463
withheld;  and  Martin P. Slark, 76,983,471  votes  in  favor  and
17,910,944 withheld.

     The  second  proposal before the stockholders, the  amendment
and  restatement  of  the 2004 Molex Incorporated  Employee  Stock
Purchase  Plan, was approved.  The number of Common  Stock  shares
voted  for  the  proposal  was 82,503,248;  against  -  6,288,159;
abstaining   -   853,562;  and  broker  non-votes   -   5,155,340.
Substantially all Class B Common Stock shares, 94,105, were  voted
for the proposal.

     The  final proposal before the stockholders, the ratification
of  Deloitte  &  Touche  LLP  as  the  independent  auditors,  was
approved.   The  number  of  Common Stock  shares  voted  for  the
proposal  was  86,404,079;  against  -  7,555,982;  abstaining   -
840,248;  and  broker non-votes - 0.  Substantially  all  Class  B
Common Stock shares, 94,105, were voted for the proposal.





Item 5.  Other Information

     Change  in Molex's Certifying Accountant.  On November  13,
2004,  Deloitte  &  Touche LLP notified Molex  that  Deloitte  was
resigning  as Molex's independent public accounting  firm.   Molex
expects  to  engage a new independent registered public accounting
firm   in  the  near  future.   A  summary  of  the  circumstances
surrounding  these developments is set forth below.    During  the
fiscal  quarter  ended  September  30,  2004,  Molex's  management
identified the omission of certain intercompany inventory  in  its
calculation of profit-in-inventory elimination for prior  periods.
Molex's  management  determined that Molex's financial  statements
for  the  fiscal quarter ended September 30, 2004 would include  a
charge of $8.0 million ($5.8 million after-tax or $0.03 per share)
related  to  the  omission  in  prior  fiscal  periods,  of  which
approximately $3.0 million ($2.2 million after-tax) was related to
fiscal  2004.  This charge was reflected in the financial  results
included  in  Molex's  October 20, 2004 earnings  release  and  is
reflected in the unaudited financial statements included  in  this

                                       15


Form  10-Q.   Molex concluded that the amounts related  to  fiscal
2004  and prior years are not material, both individually  and  in
the aggregate, to the trends of the financial statements for those
periods affected, and to a fair presentation of Molex's results of
operations and financial statements.

     Molex's independent public accounting firm, Deloitte & Touche
LLP,  expressed to the Audit Committee that the omission described
above  should  have  been disclosed in the  representation  letter
dated August 20, 2004 of Molex's Chief Executive Officer and Chief
Financial Officer delivered to Deloitte on September 10,  2004  in
connection  with the audit of Molex's financial statements  as  of
and  for  the year ended June 30, 2004 and the filing  of  Molex's
Annual Report on Form 10-K on September 10, 2004.  The signatories
did  not  believe that the matter was required to be addressed  in
that letter.

     The Audit Committee, with the assistance of independent legal
and  accounting advisors, conducted an inquiry into  the  omission
and  related  matters.  The Audit Committee of  Molex's  Board  of
Directors    concluded   that   it   concurs   with   management's
recommendations as to the accounting treatment for such  omission.
No  additional  adjustments were identified as a  result  of  this
inquiry.   The  Audit  Committee presented  the  findings  of  the
inquiry  to  Deloitte.  Deloitte requested additional  information
relating  to  this  matter and the Audit  Committee  provided  the
information responsive to those requests.

      The Molex Board of Directors on November 10 named Robert  B.
Mahoney,  a  current  Executive Vice President  and  former  Chief
Financial Officer of Molex, as the Acting Chief Financial Officer,
and  reassigned the prior Chief Financial Officer to the  position
of  Vice  President  and  Treasurer.  The Board's  action  was  in
response  to  Deloitte having advised Molex that, because  of  its
view that this matter should have been disclosed in the August 20,
2004 representation letter, Deloitte would require representations
and  certifications from a new principal accounting and  financial
officer  in  connection  with  Molex's  future  filings  with  the
Securities   and   Exchange   Commission   containing    financial
statements,  including  this  Quarterly  Report  on   Form   10-Q.
Deloitte  had  concurrently advised Molex that it was  considering
whether it would require representations and certifications from a
new  principal executive officer in connection with Molex's future
SEC filings.

      On  Saturday, November 13, 2004, representatives of Deloitte
advised  Molex that Deloitte was prepared to complete its SAS  100
review  in  time  to  permit  a  filing  of  this  Form  10-Q   in
substantially the form in which it is filed by the November
15  extended  deadline  for  such  report,  but  only  if  Molex's
principal  executive  officer and former principal  financial  and
accounting officer, who was recently reassigned as Vice  President
and  Treasurer  as described in Molex's November 11 press  release
attached  as Exhibit 99.1 hereto, no longer served as officers  of
Molex  and certain disclosures relating to the matters in question
were agreed upon.   Molex's Audit Committee and Board of Directors
each  unanimously  rejected this condition  imposed  by  Deloitte.
Following  the  communication of Molex's position, representatives
of  Deloitte advised Molex that Deloitte was resigning as  Molex's
independent  auditors  effective immediately.   Deloitte  did  not
advise   the  Company  that  its  resignation  was  due   to   any
disagreements with Molex on any matter of accounting principles or
practices,  financial statement disclosure, or auditing  scope  or
procedures which, if not resolved to the satisfaction of Deloitte,
would  have caused Deloitte to make reference thereto in its audit
report.

     Due  to the timing of Deloitte's resignation, Molex could not
retain  a  new  independent public accounting firm  prior  to  the
filing  of this Quarterly Report on Form 10-Q.  Consequently,  the
financial  statements included in this Form  10-Q  have  not  been
reviewed  by an independent public accounting firm as required  by
Rule  10-01(d)  of  Regulation S-X.  As a  result,  Molex's  Chief
Executive  Officer  and  Molex's Acting  Chief  Financial  Officer
cannot  certify  that  this  Form 10-Q "fully complies"  with  the
requirement  of  Section 13(a) or 15(d) of  the  Exchange  Act  as
required by Section 906 of the Sarbanes-Oxley Act of 2002.

     Molex  expects to engage a new independent registered  public
accounting firm in the near future.  Molex also expects  that  the
review  of  its financial statements for the fiscal quarter  ended
September  30,  2004  will be completed  as  soon  as  practicable
following   Molex's   engagement  of  a  new  independent   public
accounting firm.  Upon the completion of such review, Molex  plans
to  file  an  amendment to this Form 10-Q, which  amendment  would
include the certifications required by Section 906 of the Sarbanes-
Oxley Act of 2002.  Until such planned amendment to this Form 10-Q
is  filed, Molex is not deemed by the SEC to be current or  timely

                                       16

in  its Exchange Act filings.  After the planned amendment to this
Form  10-Q  is  filed, Molex will be current in its SEC  reporting
obligations.

     Compliance   with  Nasdaq  Continued  Listing   Requirements.
Nasdaq  Marketplace Rule 4310(c)(14) requires Molex to  file  with
the  Nasdaq  Stock Market, Inc. ("Nasdaq") copies of  all  reports
filed or required to be filed with the SEC.  On November 15, 2004,
Molex  will  have notified Nasdaq that Deloitte had  resigned  and
that  as  a result the unaudited financial statements included  in
this  Form  10-Q  filing have not been reviewed by  an  independent
registered public accounting firm.  Because the SEC does not  deem
this  Form  10-Q to be current and timely, Molex will  not  be  in
compliance  with  Nasdaq's continued listing standards  and  Molex
expects  that  Nasdaq will issue a letter to Molex regarding  such
non-compliance  and  potential delisting.   Molex  would  in  such
circumstance  appeal to the Nasdaq Hearing Panel  and  request  an
extension  sufficient  to  allow  Molex's  independent  registered
public  accounting  firm to complete its SAS 100  review  and  for
Molex to remedy such noncompliance by filing the planned amendment
to this Form 10-Q.

     Departure and Appointment of Principal Officers.  On November
10,  2004, Molex's Board of Directors appointed Robert B. Mahoney,
a  current  Executive  Vice President and former  Chief  Financial
Officer  of  Molex,  as  the Acting Chief  Financial  Officer  and
reassigned the prior Chief Financial Officer, Diane S. Bullock, to
the position of Vice President and Treasurer.

     Robert  B. Mahoney, age 51, has been employed by Molex  since
1995.   In  addition to his appointment as Acting Chief  Financial
Officer,  Mr. Mahoney will continue to serve as an Executive  Vice
President  of Molex (since 2002) and as President, Far East  South
(beginning  in 2004).  Previously, he served as Molex's  Treasurer
and  Chief  Financial Officer from 1996 to 2004 and as a Corporate
Vice  President  of Molex from 1996 to 2002. There  is  no  family
relationship  between  Mr.  Mahoney and  any  director,  executive
officer,  or  person  nominated or chosen by  Molex  to  become  a
director  or  executive officer.  There is no  written  employment
agreement between Mr. Mahoney and Molex.

     Additional Information.  You should refer to Molex's  Current
Report  on  Form  8-K dated November 15, 2004,  including  Molex's
press  release dated November 15, 2004 for additional  information
regarding the foregoing matters.  You should also refer to Molex's
November 11, 2004 press release attached hereto as Exhibit 99.1.


Cautionary Statement

     This Quarterly Report on Form 10-Q contains certain statements
that are "forward-looking statements" as defined in the Private
Securities   Litigation   Reform  Act  of  1995.   Forward-looking
statements,  in  general,  predict, forecast,  indicate  or  imply
future  results,  performance or achievements  and  are  typically
identified  by  words  or  phases  such  as  "believe",  "expect",
"estimate"   and   similar   expressions.   Such   forward-looking
statements are subject to various risks and uncertainties that may
cause  actual results or performance to vary materially from those
projected. Certain of these risks and uncertainties are set  forth
in this and other documents filed with the Securities and Exchange
Commission   and  include,  but  are  not  limited  to, Molex's
ability to timely hire a new independent registered public accounting
firm, Molex's ability to timely comply with SEC and Nasdaq reporting
obligations, economic conditions in various regions, product and price
competition, raw material prices, foreign currency exchange rates,
interest rates, changes in technology, patent issues, litigation
results and legal and regulatory developments. Molex undertakes
no obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.


Item 6.  Exhibits


     Number    Description
     ------    -----------
       31      Rule 13a-14(a)/15d-14(a) Certifications

                                       17

               31.1  Section 302 certification by Chief Executive Officer
               31.2  Section 302 certification by Acting Chief Financial Officer




       99      Additional Exhibits

               99.1  Press release dated November 11, 2004


                                       18





                            SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act
of  1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.


                                           MOLEX INCORPORATED
                                        _______________________
                                             (Registrant)



Date:  November 15, 2004                 /s/ ROBERT B. MAHONEY
                                        ______________________
                                        Robert B. Mahoney
                                        Acting Chief Financial Officer
                                        Executive Vice President, and
                                        President, Far East South



Date:  November 15, 2004                 /s/ LOUIS A. HECHT
                                        ___________________
                                        Louis A. Hecht
                                        Corporate Secretary and
                                        General Counsel




                                       19